Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. reports developments for a cardiac and vascular surgery medical device business focused on aortic disease. Recurring updates cover aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, along with preservation services for cardiac and vascular tissues and product sales across international markets.
Company news also includes quarterly and annual financial results, clinical presentations tied to NEXUS and AMDS aortic-disease programs, FDA and PMA-related regulatory developments, financing and capital-structure actions, investor conference participation, and governance matters. The company’s disclosures often connect revenue trends to stent grafts, On-X, BioGlue, preservation services, and other product categories used by cardiac and vascular surgeons.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery solutions, announced that it will release its first quarter 2023 financial results on May 4, 2023, post-market. A teleconference call and live webcast will follow at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin. Investors can access the teleconference by dialing 862-298-0702. The replay will be available within an hour post-event. This announcement emphasizes Artivion's ongoing commitment to transparency with its stakeholders regarding its financial performance. The company's innovative product lines, including aortic stent grafts and surgical sealants, aim to address complex cardiac challenges, positioning Artivion within the competitive landscape of over 100 countries globally.
Artivion, Inc. (NYSE: AORT) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 18, 2023 at 8:45 a.m. ET. The company's virtual fireside chat will focus on advancements in cardiac and vascular surgery for aortic diseases.
A live webcast will be available on Artivion's website, with an archived version accessible for 90 days. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for cardiac and vascular surgeons, offering products such as aortic stents, surgical sealants, On-X mechanical heart valves, and implantable human tissues, distributed in over 100 countries.